Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 22 Sep 2016
CADTH calls for patient input on a resubmission from NovoNordisk for Victoza (liraglutide)
21 September 2016 - CADTH is calling for patient input on a resubmission from Novo Nordisk for Victoza (liraglutide). ...
Posted by Michael Wonder on 31 Aug 2016
Schedule of Pharmaceutical Benefits - 1 September 2016 update
1 September 2016 - The 1 September 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada. ...
Posted by Michael Wonder on 14 Aug 2016
Type 2 diabetes boost: new treatment will save money and multiple injections
14 August 2016 - Thousands of Australians with type 2 diabetes mellitus will soon be able to have one injection a ...
Posted by Michael Wonder on 11 Aug 2016
CADTH provides an update on its therapeutic review of new drugs for type 2 diabetes mellitus
10 August 2016 - CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment ...
Posted by Michael Wonder on 18 Jul 2016
Diabetes drugs cost the NHS in Scotland almost £90 million last year
16 July 2016 - Diabetes drugs cost the NHS in Scotland almost £90 million last year amid fears that public health ...
Posted by Michael Wonder on 25 May 2016
NICE recommends three diabetes treatments
24 May 2016 - The three drugs can all be used on their own if a person can’t use metformin or ...
Posted by Michael Wonder on 30 Mar 2016
Call for patient input on a submission from Boehringer Ingelheim for Jardiance (empagliflozin)
30 March 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for empagliflizin (Jardiance) for use by ...
Posted by Michael Wonder on 23 Feb 2016
Call for feedback: new drugs for type 2 diabetes: a therapeutic review update
22 February 2016 - A proposed CADTH project scope on new drugs for type 2 diabetes mellitus: a therapeutic review update ...
Posted by Michael Wonder on 03 Feb 2016
CADTH calls for patient input on a new submission from Janssen-Cilag for canagliflozin hemihydrate with metformin hydrochloride
3 February 2016 - CADTH has received notice of a pending submission from Janssen-Cilag for canagliflozin hemihydrate with metformin hydrochloride for ...
Posted by Michael Wonder on 01 Dec 2015
CADTH calls for patient input on a new submission from AstraZeneca for Xigduo
1 December 2015 - CADTH has received notice of a pending submission from AstraZeneca for Xigduo (dapagliflozin propanediol monohydrate with metformin ...
Posted by Michael Wonder on 18 Nov 2015
Insulin degludec plus liraglutide: again no hint of added benefit in type 2 diabetes says IQWiG
16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus ...
Posted by Michael Wonder on 17 Nov 2015
CADTH calls for patient input on a new submission from Eli Lilly for Trulicity
17 November 2015 - CADTH has received notice of a pending submission from Eli LIlly for dulaglutide (Trulicity) for use by ...